Details for Patent: 8,669,279
✉ Email this page to a colleague
Which drugs does patent 8,669,279 protect, and when does it expire?
Patent 8,669,279 protects TREANDA and is included in one NDA.
Protection for TREANDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventeen patent family members in eleven countries.
Summary for Patent: 8,669,279
| Title: | Solid forms of bendamustine hydrochloride |
| Abstract: | Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. |
| Inventor(s): | Cooper; Martin Ian (Foxton, GB), Courvoisier; Laurent D. (Thorndale, PA), Eddleston; Mark (Chillwell, GB), McKean; Robert E. (Chester Springs, PA) |
| Assignee: | Cephalon, Inc. (Frazer, PA) |
| Application Number: | 13/874,575 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,669,279 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,669,279
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cephalon | TREANDA | bendamustine hydrochloride | POWDER;INTRAVENOUS | 022249-002 | May 1, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cephalon | TREANDA | bendamustine hydrochloride | POWDER;INTRAVENOUS | 022249-001 | Mar 20, 2008 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
